Ms. Ann Marie Davidczyk, Vice President Patient Access and Advocacy, Blue Earth Diagnostics discusses Next Generation Precision Radiopharmaceuticals for Patients with Cancer

Ms. Ann Marie Dawidczyk, Vice President Patient Access and Advocacy, Blue Earth Diagnostics

At the 2021 African American Prostate Cancer Disparity Summit, Ms. Ann Marie Dawidczyk, Vice President of Patient Access and Advocacy at Blue Earth Diagnostics, presented on next generation precision radiopharmaceuticals for cancer patients. Blue Earth Diagnostics moves pre-clinical therapeutic products to Phase III trials in the realm of diagnostic imaging. Fluciclovine F 18 is one such product originally invented at Emory University and commercialized by Blue Earth. This molecule is used in an injection for PET scans to assess prostate cancer recurrence.